JUBLPHARMA1,026.00

Jubilant Pharmova Ltd.

· Pharma & Health
₹ CrorePeersGLANDPPLPHARMAKIMSINDGNONESOURCEGRANULESPFIZERPOLYMEDMcap ₹16,211 Cr
ProfitabilityGrowthCreditLiquidityWorking CapitalYield AnalysisDuPont
Ratios — % unless marked ×
12 Months Ending
FY24
31/03/2024
FY25
31/03/2025
FY26
31/03/2026
Last 12M
30/06/2026
Inventory Days (DIO)258.44207.60193.72193.72
Receivable Days (DSO)49.8744.9847.1547.15
Payable Days (DPO)171.61184.73194.13184.75
Cash Conversion Cycle (days)136.7067.8546.7456.12
Working Capital Turnover3.855.385.275.48
Asset Turnover0.580.570.530.53
Cash Conversion (CFO/Net Income)13.361.283.093.09
CFO/EBITDA1.080.910.970.97
No consensus estimates → no Est columns. Click any row to chart it.
« ‹ › »Latest: FY26 · ConsolidatedFA Financial Analysis · alphave
Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreementXBRL cross-verified ✓ 95%.